Short-course treatment of community-acquired pneumonia

Clinical Infectious Diseases

Volumn 37, Issue 6, 2003, Pages 761-763

  Mandell, Lionel A ^a   File Jr , Thomas M ^b  

^a HENDERSON GENERAL HOSPITAL   (Canada)

^b SUMMA HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; AZITHROMYCIN; BETA LACTAM ANTIBIOTIC; CIPROFLOXACIN; CLARITHROMYCIN; LEVOFLOXACIN; MACROLIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TELITHROMYCIN;

ANTIBIOTIC THERAPY; BACTERICIDAL ACTIVITY; CLINICAL TRIAL; COMMUNITY ACQUIRED PNEUMONIA; DRUG MEGADOSE; HUMAN; NOTE; PENICILLIN RESISTANCE; PNEUMONIA; PRIORITY JOURNAL; SHORT COURSE THERAPY; SIDE EFFECT; STREPTOCOCCUS PNEUMONIAE;

ANTI-BACTERIAL AGENTS; COMMUNITY-ACQUIRED INFECTIONS; DRUG ADMINISTRATION SCHEDULE; HUMANS; PNEUMONIA, BACTERIAL; TREATMENT OUTCOME;

EID: 0141453234     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/377567     Document Type: Note

References (10)

1. Schrag SJ, Pena C, Fernandez J, et al. Effect of short-course, high-dose amoxicillin therapy on resistant pneumococcal carriage: a randomized trial. JAMA 2001; 286:49-56.
2. Dunbar LM, Wunderink RG, Habib MP, et al. High-dose, short-course levofloxacin for community acquired pneumonia: a new treatment paradigm. Clin Infect Dis 2003; 37:752-60 (in this issue).
3. O'Doherty B, Muller O. Randomized, multicentre study of the efficacy and tolerance of azithromycin versus clarithromycin in the treatment of adults with mild to moderate community acquired pneumonia. Azithromycin Study Group. Eur J Clin Microbiol Infect Dis 1998; 17:828-33.
4. Hoepelman IM, Mollers MJ, van Schie MH, et al. A short (3-day) course of azithromycin tablets versus a 10-day course of amoxicillin-clavulanic acid (co-amoxiclav) in the treatment of adults with lower respiratory tract infections and effects on long-term outcome. Int J Antimicrob Agents 1997; 9:141-6.
5. Tellier G, Isakov T, Petermann W, Patel M, Lavin B. Efficacy and safety of telithromycin (800 mg once daily) for 5 or 7 days vs clarithromycin (500 mg twice daily) for 10 days in the treatment of patients with community acquired pneumonia [abstract L-373]. In: Program and abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington, DC: American Society for Microbiology, 2002:346.
6. Preston SL, Drusano GL, Berman AL, et al. Prospective development of pharmacodynamic relationships between measures of levofloxacin exposure and measures of patient outcome: a new paradigm for early clinical trials. JAMA 1998; 279:125-9.
7. Lister PD. Pharmacodynamics of 750 mg and 500 mg doses of levofloxacin against ciprofloxacin-resistant strains of Streptococcus pneumoniae. Diagn Microbiol Infect Dis 2002; 44:43-9.
8. Gotfried MH, Danzinger LH, Rodvold KA. Steady-state plasma and intrapulmonary concentrations of levofloxacin and ciprofloxacin in healthy adult subjects. Chest 2001; 119:1114-22.
9. Dennesen P, Vanderven A, Kessels A, Ramsay G, Bonten M. Resolution of infectious parameters after antimicrobial therapy in patients with ventilator-associated pneumonia. Am J Respir Crit Care Med 2001; 163:1371-5.
10. Luna CM, Blanzaco D, Niederman MS, et al. Resolution of ventilator associated pneumonia: prospective evaluation of the clinical pulmonary infection score as an early clinical predictor of outcome. Crit Care Med 2003; 31:676-82.